Ken Griffin Design Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.19 - $5.88 $13,717 - $25,284	-4,300 Reduced 61.43%	2,700 $14,000
Q2 2024 Aug 14, 2024	BUY	$3.23 - $4.77 $22,287 - $32,913	6,900 Added 6900.0%	7,000 $23,000
Q1 2024 May 15, 2024	SELL	$2.27 - $4.03 $6,583 - $11,687	-2,900 Reduced 96.67%	100 $0
Q4 2023 Feb 14, 2024	SELL	$1.99 - $2.76 $1,393 - $1,931	-700 Reduced 18.92%	3,000 $7,000
Q3 2023 Nov 14, 2023	SELL	$2.05 - $8.14 $1,025 - $4,070	-500 Reduced 11.9%	3,700 $8,000
Q2 2023 Aug 14, 2023	SELL	$4.99 - $7.64 $21,956 - $33,616	-4,400 Reduced 51.16%	4,200 $26,000
Q1 2023 May 15, 2023	SELL	$5.5 - $9.77 $16,500 - $29,310	-3,000 Reduced 25.86%	8,600 $49,000
Q4 2022 Feb 14, 2023	BUY	$7.86 - $17.2 $91,176 - $199,520	11,600 New	11,600 $119,000

102

31M

2.3K

16.5K

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $349M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.